SINOMED(SH:688108)2025-04-25 14:53Financial Performance - The company's operating revenue for Q1 2024 was ¥91,062,636.90, representing a year-on-year increase of 24.46%[5] - The net profit attributable to shareholders was -¥1,672,840.41, with a significant increase in net loss compared to the previous year[5] - Total revenue for Q1 2024 reached ¥91,062,636.90, a 24.4% increase from ¥73,168,207.49 in Q1 2023[18] - Net profit for Q1 2024 was a loss of ¥3,684,677.11, an improvement from a loss of ¥18,642,741.10 in Q1 2023[19] - Total comprehensive income for Q1 2024 was a loss of ¥5,003,621.26, compared to a loss of ¥19,139,644.82 in Q1 2023[19] Research and Development - Research and development expenses totaled ¥40,560,514.19, accounting for 44.54% of operating revenue, an increase of 2.99 percentage points year-on-year[6] - The company added eLum to its consolidated scope, contributing to increased R&D costs across various categories[9] - Research and development expenses rose to ¥36,009,056.49 in Q1 2024, up 35.4% from ¥26,583,394.30 in Q1 2023[18] - Research and development expenses for Q1 2024 were CNY 7,076,116.53, down from CNY 8,715,645.88 in Q1 2023, reflecting a decrease of approximately 18.8%[28] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,275,418,626.59, reflecting a 7.56% increase from the end of the previous year[6] - The company's total current assets rose to CNY 307,807,885.11, compared to CNY 286,299,842.73 at the end of 2023, marking an increase of about 7.4%[24] - The total liabilities of the company were RMB 395,630,423.74, which is an increase from RMB 324,171,588.85, representing a growth of around 22.1%[15] - The company's long-term liabilities increased to RMB 235,587,162.35 from RMB 172,899,093.28, representing a growth of approximately 36.3%[15] - The total liabilities increased to CNY 301,940,030.53 as of March 31, 2024, compared to CNY 240,066,782.01 at the end of 2023, showing an increase of about 25.7%[25] Cash Flow - Operating cash flow for Q1 2024 showed a net outflow of ¥16,218,315.41, compared to a net outflow of ¥19,993,202.99 in Q1 2023[21] - The company generated ¥87,527,487.94 in cash from financing activities in Q1 2024, compared to ¥17,000,000.00 in Q1 2023[22] - The net cash flow from operating activities was -CNY 9,478,350.67, an improvement from -CNY 12,337,600.64 in the same period last year[30] - The net cash flow from financing activities was CNY 72,818,883.96, up from CNY 19,298,666.67 in Q1 2023, indicating a strong increase in financing[31] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,173, with the largest shareholder holding 17.53% of the shares[10] - The company's equity attributable to shareholders was RMB 817,378,486.78, slightly down from RMB 819,957,004.39, showing a decrease of about 0.3%[16] - The total owner's equity reached CNY 1,103,981,155.96 as of March 31, 2024, slightly up from CNY 1,099,238,457.97 at the end of 2023, reflecting a growth of about 0.4%[25] Earnings Per Share - The basic and diluted earnings per share were both -¥0.004, indicating a 90% increase in loss per share compared to the previous year[9] - Basic and diluted earnings per share for Q1 2024 were both -¥0.004, an improvement from -¥0.04 in Q1 2023[19]